Armata Pharmaceuticals (ARMP) Investor presentation summary

Study design and methodology

• Phase 2a randomized, double-blind, controlled trial compared intravenous AP-SA02 phage cocktail plus best available antibiotics (BAT) to placebo in complicated Staphylococcus aureus bacteremia (SAB) across 28 sites.

• AP-SA02 is a two-phage cocktail (ARSA0001 and ARSA0002) dosed IV every 6 hours for 5 days, with patients also receiving standard-of-care antibiotics.

• Responder status required resolution of temperature, heart rate, respiratory rate, white blood cell count, systolic blood pressure, and infection site pain.

• Demographics: mean age ~54 years, majority male, diverse infection sites including osteomyelitis, sepsis, and endocarditis.

• Antibiotics used included cefazolin, vancomycin, oxacillin/nafcillin, daptomycin, cefepime, and ceftriaxone, with some patients receiving multiple agents.

Efficacy and clinical outcomes

• AP-SA02 plus BAT showed significantly higher and earlier cure rates than placebo at day 12, post-BAT, and end of study (EOS).

• In MRSA and MSSA subgroups, AP-SA02 demonstrated higher rates of infection clearance and lower relapse compared to placebo.

• AP-SA02 group had shorter mean time to hospital discharge (11.7 vs. 19.2 days) and faster SAB resolution (2.7 vs. 9.3 days) than placebo.

• Lower mean CRP at day 12 in AP-SA02 group (50.2 mg/L) versus placebo (97.3 mg/L), indicating reduced inflammation.

Safety and tolerability

• AP-SA02 was safe and well tolerated, with similar rates of adverse events and serious adverse events compared to placebo.

• No increase in study drug-related adverse events; transient liver enzyme elevations resolved without intervention.

• No deaths attributed to AP-SA02 or study antibiotics.